{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}],"title":"Prophylaxis for CAR T-cell administration"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Length of hospitalization stay was reported for up to 24 months post liso-cel infusion. Reasons for hospitalization include adverse events, prophylaxis, and other. Adverse events were reported for up to 90 days post liso-cel infusion.","groups":[{"description":"Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.","id":"OG000","title":"Lisocabtagene Maraleucel (JCAR017)"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one infusion of JCAR017 who were monitored inpatient","reportingStatus":"POSTED","timeFrame":"From first dose after JCAR017 infusion to up to approximately 24 months","title":"The Number of Participants That Were Hospitalized For Adverse Events, Prophylaxis, Other","type":"SECONDARY","unitOfMeasure":"Participants"}